Global mRNA Vaccine Raw Materials Market Growth (Status and Outlook) 2024-2030

Global mRNA Vaccine Raw Materials Market Growth (Status and Outlook) 2024-2030

The development and production of mRNA vaccines is relatively simple, scalable, and extremely rapid. mRNA is produced in vitro through an enzymatic process without the need to remove cells or host cell proteins. This simplified production process allows GMP facilities to be converted to produce new protein targets in a very short period of time, with only minimal changes to the process and formulation.

The global mRNA Vaccine Raw Materials market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “mRNA Vaccine Raw Materials Industry Forecast” looks at past sales and reviews total world mRNA Vaccine Raw Materials sales in 2022, providing a comprehensive analysis by region and market sector of projected mRNA Vaccine Raw Materials sales for 2023 through 2029. With mRNA Vaccine Raw Materials sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Vaccine Raw Materials industry.

This Insight Report provides a comprehensive analysis of the global mRNA Vaccine Raw Materials landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on mRNA Vaccine Raw Materials portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global mRNA Vaccine Raw Materials market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Vaccine Raw Materials and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Vaccine Raw Materials.

United States market for mRNA Vaccine Raw Materials is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for mRNA Vaccine Raw Materials is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for mRNA Vaccine Raw Materials is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key mRNA Vaccine Raw Materials players cover Thermo Fisher Scientific Inc., Danaher Corporation, Kaneka Eurogentec S.A., BioSpring, GenScript, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Vaccine Raw Materials market by product type, application, key players and key regions and countries.

Segmentation by Type:
Plasmid DNA (pDNA)
Enzyme
Other

Segmentation by Application:
(non-replicating) mRNA vaccine
(self-amplifying) mRNA vaccine

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Plasmid DNA (pDNA)
Enzyme
Other

Segmentation by Application:
(non-replicating) mRNA vaccine
(self-amplifying) mRNA vaccine

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific Inc.
Danaher Corporation
Kaneka Eurogentec S.A.
BioSpring
GenScript
Aji Bio-Pharma
Merck KGaA
Aldevron
Hongene
WuXi Biologics
Asymchem
Cosychem
Novoprotein
Vazyme
Yeasen
KACTUS

Please note: The report will take approximately 2 business days to prepare and deliver.